- Home
- NSSC vs PRAX Comparison
NSSC vs PRAX Comparison
Compare NSSC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- PRAX
- Stock Information
- Founded
- NSSC 1969
- PRAX 2015
- Country
- NSSC United States
- PRAX United States
- Employees
- NSSC N/A
- PRAX N/A
- Industry
- NSSC Telecommunications Equipment
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- NSSC Telecommunications
- PRAX Health Care
- Exchange
- NSSC Nasdaq
- PRAX Nasdaq
- Market Cap
- NSSC 1.1B
- PRAX 950.8M
- IPO Year
- NSSC N/A
- PRAX 2020
- Fundamental
- Price
- NSSC $42.06
- PRAX $45.93
- Analyst Decision
- NSSC Strong Buy
- PRAX Strong Buy
- Analyst Count
- NSSC 6
- PRAX 9
- Target Price
- NSSC $37.67
- PRAX $94.44
- AVG Volume (30 Days)
- NSSC 515.0K
- PRAX 383.5K
- Earning Date
- NSSC 11-03-2025
- PRAX 11-05-2025
- Dividend Yield
- NSSC 1.30%
- PRAX N/A
- EPS Growth
- NSSC N/A
- PRAX N/A
- EPS
- NSSC 1.19
- PRAX N/A
- Revenue
- NSSC $181,621,000.00
- PRAX $7,765,000.00
- Revenue This Year
- NSSC $5.13
- PRAX N/A
- Revenue Next Year
- NSSC $11.41
- PRAX $22.22
- P/E Ratio
- NSSC $36.08
- PRAX N/A
- Revenue Growth
- NSSC N/A
- PRAX 338.45
- 52 Week Low
- NSSC $19.00
- PRAX $26.70
- 52 Week High
- NSSC $44.24
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- NSSC 69.17
- PRAX 52.99
- Support Level
- NSSC $39.81
- PRAX $37.25
- Resistance Level
- NSSC $44.24
- PRAX $40.69
- Average True Range (ATR)
- NSSC 1.23
- PRAX 2.52
- MACD
- NSSC 0.09
- PRAX 0.30
- Stochastic Oscillator
- NSSC 61.80
- PRAX 79.61
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.